

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4390776

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVO NORDISK A/S	03/16/2009
RECEIVING PARTY DATA	
Name:	TransTech Pharma, Inc.
Street Address:	4170 Mendenhall Oaks Parkway
City:	High Point
State/Country:	NORTH CAROLINA
Postal Code:	27265
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15490205
CORRESPONDENCE DATA	
Fax Number:	(336)841-7020
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	336-841-0300
Email:	patentmail@vtvtherapeutics.com
Correspondent Name:	SAMUEL B. ROLLINS
Address Line 1:	4170 MENDENHALL OAKS PARKWAY
Address Line 4:	HIGH POINT, NORTH CAROLINA 27265
ATTORNEY DOCKET NUMBER:	7253.244-US
NAME OF SUBMITTER:	SAMUEL B. ROLLINS
SIGNATURE:	/Samuel B. Rollins/
DATE SIGNED:	04/28/2017
Total Attachments: 3	
source=3. Assignment (Novo to TTP)#page1.tif	
source=3. Assignment (Novo to TTP)#page2.tif	
source=3. Assignment (Novo to TTP)#page3.tif	

PATENT ASSIGNMENT

WHEREAS, NOVO NORDISK A/S (hereafter "Assignor"), a corporation organized under the laws of Denmark, having an address of Novo Alle, DK-2880 Bagsvaerd, Denmark, is the owner of the patent(s) and/or patent application(s) set forth on Exhibit A hereto and the inventions described and claimed therein (hereafter the "Patent Property"); and

WHEREAS, TRANSTECH PHARMA, INC. (hereafter "Assignee"), a Delaware Corporation, having an address of 4170 Mendenhall Oaks Parkway, High Point, North Carolina, 27265, desires to acquired all right, title and interest in and to the Patent Property.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer and set over to Assignee, all its right, title and interest in and to the Patent Property, as well as all priority applications, provisionals, continuations, divisions, continuations-in-part, of said Patent Property, and all reissues, reexaminations, and extensions thereof, the same to be held and enjoyed by Assignee for its own use and benefit, and for the use and benefit of its successors, assigns, or legal representatives, to the end of the term or terms for which such Patent Property may be granted or reissued, as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made.

Assignor also assigns to Assignee, all right, title and interest in and to the inventions disclosed in said Patent Property throughout the world, including the right to file applications and obtain patents, utility models, industrial models and designs for said Patent Property in its own name throughout the world, including all rights to publish cautionary notices reserving ownership of said inventions and all rights to register said Patent Property in appropriate registries.

IN WITNESS WHEREOF, the parties have caused this Patent Assignment to be executed
on the date and in the capacity shown below.

NOVO NORDISK A/S



By: 	By: 
Name: <u>Kåre Schultz</u>	Name: _____
Title: <u>Chief Operating Officer</u> Novo Nordisk A/S	Title: <u>Lise Kingo</u> Executive vice president and chief of staffs Corporate Relations
Date: <u>16.03.09</u>	Date: <u>16 March 2009</u>

Exhibit A

Schedule of Patents/Patent Applications

U.S. Application No.	U.S. Registration No.
10/370,856	6,867,218
09/770,896	6,555,577
09/551,740	6,972,294
11/917,811	
10/217,595	7,067,530
10/272,613	7,220,877
10/201,456	6,869,967
11/579,303	
10/654,699	7,091,245
10/693,161	7,129,268
10/734,368	
11/439,827	
11/579,716	
11/579,717	
11/579,712	
09/771,217	6,569,901
10/442,284	7,202,213
12/097,564	